Aclaris Therapeutics is a biopharmaceutical company focused on immuno-inflammatory diseases. Co.'s pipeline of drug candidates includes: ATI-450 mitogen-activated protein kinase-activated protein kinase 2 Inhibitor Oral for the indication of Rheumatoid Arthritis plus Additional Immuno-inflammatory Indication; and ATI-1777 Janus kinase (JAK)1/JAK3 Inhibitor Soft Topical for the indication of Atopic Dermatitis. ESKATA, Co.'s only U.S. Food and Drug Administration (FDA)-approved product, is a formulation of high-concentration hydrogen peroxide topical solution which is approved by the FDA as an office-based prescription treatment for raised seborrheic keratosis, a non-malignant skin tumor. We show 21 historical shares outstanding datapoints in our coverage of ACRS's shares outstanding history.
Understanding the changing numbers of ACRS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACRS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACRS by allowing them to research ACRS shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
